GLP-1 Receptor Agonists for Binge Eating Disorder in a Patient with Type 2 Diabetes
Semaglutide is approved for his diabetes and his weight, but not for the binge eating disorder actually driving both. Early evidence suggests it might help the bingeing directly, not just the weight — but 'might' is doing a lot of work in a population where appetite suppression itself is not automatically a safe thing to induce.
F.O., a 52-year-old man, has supervised a regional distribution warehouse for eleven years, work that keeps him on his feet for long stretches but, by his own description, hasn't kept pace with what sitting in a break room eating from a vending machine most nights has done to him over that same decade. He was diagnosed with type 2 diabetes six years ago, managed since on metformin with an A1c that has crept upward despite reasonably consistent medication adherence, and was screened for binge eating disorder eight months ago after his endocrinologist noticed a pattern in his food logs that looked less like general overeating and more like discrete, out-of-control episodes — usually late at night, usually alone, always followed by real distress the next morning that he described candidly once asked directly.
Semaglutide is already on the table for his diabetes and weight — a use his insurance covers and his endocrinologist supports without reservation. What today's joint consultation is actually deciding is something narrower: whether to frame and use it specifically as a treatment for his binge eating disorder, not just as incidental to his metabolic care. The distinction matters because the evidence base for each is genuinely different. GLP-1 agonism is FDA-approved for type 2 diabetes and for chronic weight management, well-established through large trials on those endpoints. Its use for binge eating disorder specifically is a separate, much newer question. Richards and colleagues' 2023 retrospective cohort study of semaglutide in patients with binge eating disorder reported a real reduction in binge frequency that the authors argued looked at least partly independent of weight loss alone, plausibly through GLP-1's effects on satiety signaling and reward-related eating rather than simple caloric restriction. That evidence is real but genuinely preliminary — a single retrospective cohort, not a randomized trial, and nothing at the scale or rigor of the trials that earned semaglutide its actual approvals. The harder question underneath the evidence question is one the psychiatric literature on eating disorders raises independent of GLP-1 specifically: does pharmacologically suppressing appetite in a patient whose relationship to eating is already disordered by loss-of- control episodes carry a distinct risk — not of undertreatment, but of nudging the disorder toward a different, more restrictive phenotype rather than resolving it. Nobody in the room believes that risk is proven. Nobody believes it's ruled out either.
Joint endocrinology-psychiatry consultation
I want to start semaglutide today, and I'd like to tell F.O. directly that we think it may help the binge eating too, not just his A1c. Richards and colleagues' 2023 retrospective cohort study reported reduced binge frequency with semaglutide that the authors described as at least partly independent of weight loss alone — plausibly a satiety-signaling effect, not just eating less because less appeals to him. Given he already has clearly indicated diabetes and obesity, I don't see a reason to hold back the binge-specific framing if there's real reason to think it applies.
I'd separate the drug decision from the framing decision. Starting semaglutide for his diabetes and weight is clearly right — I'm not questioning that. What concerns me is calling it a binge- eating-disorder treatment to him directly, on evidence that's still open-label and preliminary, nowhere near the scale of what actually earned this drug its real approvals. There's a separate, independent concern from the eating-disorder literature more broadly: pharmacologically suppressing appetite in someone whose relationship to eating already involves loss of control can, in some patients, shift the pattern toward restriction rather than resolve it — not because the drug fails, but because it succeeds at appetite suppression in a population where that's not automatically a safe thing to induce.
I don't think that risk is proven for F.O. specifically, and I want to be honest that it isn't — I just don't think "the evidence might apply" and "let's tell him it's treating his binges" are the same level of confidence.
I don't think we actually need to resolve the framing question tonight to make a good decision. Start semaglutide now — the diabetes and weight indications are clearly met and well-evidenced on their own, no debate needed there. But track binge frequency explicitly as a monitored outcome at follow-up, rather than stating it as a treatment target today. That gives us real data on how F.O. actually responds without either overselling preliminary evidence to him or ignoring a plausible benefit if it turns out to be real. If binge frequency drops without any sign of the restriction- shift pattern flagged as a concern, that's useful information for his case specifically going forward — not something we need to have already decided.
Agreed: start semaglutide today for the clearly indicated, well-evidenced diabetes and weight management uses. Binge frequency and eating patterns will be explicitly tracked at each follow-up visit as a monitored outcome, with specific attention to any emerging restrictive pattern, without stating the binge eating disorder itself as a treatment target to F.O. at this visit.
Not agreed, and genuinely unresolved rather than deferred to a clear future decision point: at what threshold of observed benefit — or observed restriction-shift risk — the team would revisit how explicitly to frame the drug's role in his binge eating going forward. The Endocrinologist believes a clear reduction in binge frequency over the next two visits should be enough to name it directly to F.O. as part of what's helping him; the Eating Disorder Therapist wants a more structured eating-disorder-specific reassessment, not just frequency counting, before making that call either way. No specific follow-up protocol was agreed to bridge that difference.
Educational content only — a composite teaching case, not a real patient encounter or a substitute for clinical guidance. About These Cases →